HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

NASDAQ:HIVE • CA4339211035

2.14 USD
-0.14 (-6.14%)
At close: Feb 27, 2026
2.17 USD
+0.03 (+1.4%)
After Hours: 2/27/2026, 8:08:38 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

HIVE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 276 industry peers in the Software industry. HIVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, HIVE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • HIVE had negative earnings in the past year.
  • In the past year HIVE had a positive cash flow from operations.
  • In multiple years HIVE reported negative net income over the last 5 years.
  • HIVE had a positive operating cash flow in each of the past 5 years.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • With a Return On Assets value of -11.53%, HIVE is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -12.87%, HIVE is in line with its industry, outperforming 43.84% of the companies in the same industry.
Industry RankSector Rank
ROA -11.53%
ROE -12.87%
ROIC N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HIVE has more shares outstanding than it did 1 year ago.
  • HIVE has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for HIVE has been reduced compared to a year ago.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • HIVE has an Altman-Z score of 4.23. This indicates that HIVE is financially healthy and has little risk of bankruptcy at the moment.
  • HIVE has a Altman-Z score of 4.23. This is in the better half of the industry: HIVE outperforms 73.91% of its industry peers.
  • HIVE has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.03, HIVE is doing good in the industry, outperforming 61.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACCN/A
WACC10.29%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • HIVE has a Current Ratio of 1.74. This is a normal value and indicates that HIVE is financially healthy and should not expect problems in meeting its short term obligations.
  • HIVE has a Current ratio of 1.74. This is comparable to the rest of the industry: HIVE outperforms 51.45% of its industry peers.
  • HIVE has a Quick Ratio of 1.74. This is a normal value and indicates that HIVE is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.74, HIVE perfoms like the industry average, outperforming 52.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • HIVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -763.33%.
  • Looking at the last year, HIVE shows a very strong growth in Revenue. The Revenue has grown by 112.51%.
  • Measured over the past years, HIVE shows a very strong growth in Revenue. The Revenue has been growing by 31.59% on average per year.
EPS 1Y (TTM)-763.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3800%
Revenue 1Y (TTM)112.51%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%218.56%

3.2 Future

  • The Earnings Per Share is expected to decrease by -154.47% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 70.28% on average over the next years. This is a very strong growth
EPS Next Y-258.82%
EPS Next 2Y92.38%
EPS Next 3Y-154.47%
EPS Next 5YN/A
Revenue Next Year189.3%
Revenue Next 2Y106.46%
Revenue Next 3Y70.28%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • HIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 66.21 indicates a quite expensive valuation of HIVE.
  • HIVE's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. HIVE is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 66.21
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HIVE indicates a rather cheap valuation: HIVE is cheaper than 90.94% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.2
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as HIVE's earnings are expected to decrease with -154.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y92.38%
EPS Next 3Y-154.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (2/27/2026, 8:08:38 PM)

After market: 2.17 +0.03 (+1.4%)

2.14

-0.14 (-6.14%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-15
Earnings (Next)06-24
Inst Owners25.21%
Inst Owner Change39.02%
Ins Owners0.23%
Ins Owner Change0%
Market Cap536.97M
Revenue(TTM)257.14M
Net Income(TTM)-71.97M
Analysts80
Price Target4.76 (122.43%)
Short Float %9.68%
Short Ratio2.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-254.08%
Min EPS beat(2)-423.34%
Max EPS beat(2)-84.82%
EPS beat(4)2
Avg EPS beat(4)-34.38%
Min EPS beat(4)-423.34%
Max EPS beat(4)269.73%
EPS beat(8)6
Avg EPS beat(8)19.63%
EPS beat(12)8
Avg EPS beat(12)17.68%
EPS beat(16)9
Avg EPS beat(16)-129.51%
Revenue beat(2)1
Avg Revenue beat(2)5.59%
Min Revenue beat(2)-5.73%
Max Revenue beat(2)16.9%
Revenue beat(4)2
Avg Revenue beat(4)3.24%
Min Revenue beat(4)-5.73%
Max Revenue beat(4)16.9%
Revenue beat(8)5
Avg Revenue beat(8)4.17%
Revenue beat(12)8
Avg Revenue beat(12)4.05%
Revenue beat(16)11
Avg Revenue beat(16)14.48%
PT rev (1m)-26.65%
PT rev (3m)-7.27%
EPS NQ rev (1m)-181.25%
EPS NQ rev (3m)-800%
EPS NY rev (1m)0%
EPS NY rev (3m)-156.25%
Revenue NQ rev (1m)-20.98%
Revenue NQ rev (3m)-27.12%
Revenue NY rev (1m)2.44%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 66.21
P/S 2.09
P/FCF N/A
P/OCF 6.26
P/B 0.96
P/tB 0.96
EV/EBITDA 9.2
EPS(TTM)-0.26
EYN/A
EPS(NY)0.03
Fwd EY1.51%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)0.34
OCFY15.98%
SpS1.02
BVpS2.23
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.53%
ROE -12.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.3
Cap/Depr 140.42%
Cap/Sales 72.89%
Interest Coverage N/A
Cash Conversion 183.62%
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z 4.23
F-Score5
WACC10.29%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-763.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3800%
EPS Next Y-258.82%
EPS Next 2Y92.38%
EPS Next 3Y-154.47%
EPS Next 5YN/A
Revenue 1Y (TTM)112.51%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%218.56%
Revenue Next Year189.3%
Revenue Next 2Y106.46%
Revenue Next 3Y70.28%
Revenue Next 5YN/A
EBIT growth 1Y-67.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.98%
EBIT Next 3Y75.96%
EBIT Next 5YN/A
FCF growth 1Y-516.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y174.74%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%

HIVE DIGITAL TECHNOLOGIES LT / HIVE FAQ

Can you provide the ChartMill fundamental rating for HIVE DIGITAL TECHNOLOGIES LT?

ChartMill assigns a fundamental rating of 3 / 10 to HIVE.


Can you provide the valuation status for HIVE DIGITAL TECHNOLOGIES LT?

ChartMill assigns a valuation rating of 1 / 10 to HIVE DIGITAL TECHNOLOGIES LT (HIVE). This can be considered as Overvalued.


Can you provide the profitability details for HIVE DIGITAL TECHNOLOGIES LT?

HIVE DIGITAL TECHNOLOGIES LT (HIVE) has a profitability rating of 2 / 10.


What is the earnings growth outlook for HIVE DIGITAL TECHNOLOGIES LT?

The Earnings per Share (EPS) of HIVE DIGITAL TECHNOLOGIES LT (HIVE) is expected to decline by -258.82% in the next year.